Analyst Ratings for [INSM] Insmed, Inc.

2/25/25	Initiated	Outperform	X
INSM Insmed RBC Capital Mkts
$100
4/23/24	Initiated	Buy	X
INSM Insmed Truist
$48
2/15/24	Initiated	Outperform	X
INSM Insmed Wolfe Research
$42
12/8/23	Initiated	Overweight	X
INSM Insmed Wells Fargo
$55
11/20/23	Resumed	Overweight	X
INSM Insmed JP Morgan
$36
7/26/23	Initiated	Buy	X
INSM Insmed Guggenheim
$50
12/9/22	Initiated	Buy	X
INSM Insmed Mizuho
$28
12/7/22	Initiated	Overweight	X
INSM Insmed Barclays
$37
11/18/22	Initiated	Buy	X
INSM Insmed BofA Securities
$39
4/27/22	Initiated	Buy	X
INSM Insmed Goldman
$56
10/19/21	Resumed	Buy	X
INSM Insmed Monness Crespi & Hardt
$52
10/19/21	Resumed	Overweight	X
INSM Insmed Morgan Stanley
$56 $52
10/8/21	Initiated	Overweight	X
INSM Insmed Cantor Fitzgerald
$60
4/26/21	Resumed	Outperform	X
INSM Insmed Credit Suisse
$60
4/9/19	Reiterated	Buy	X
INSM Insmed H.C. Wainwright
$43 $52
2/15/19	Upgrades	Mkt Perform Mkt Outperform	X
INSM Insmed JMP Securities
$40
1/17/19	Upgrades	Neutral Buy	X
INSM Insmed Goldman
1/2/19	Initiated	Buy	X
INSM Insmed Canaccord Genuity
$20
8/6/18	Downgrades	Mkt Outperform Mkt Perform	X
INSM Insmed JMP Securities
7/23/18	Initiated	Neutral	X
INSM Insmed Goldman
$32
4/23/18	Upgrades	Neutral Outperform	X
INSM Insmed Credit Suisse
3/21/18	Initiated	Overweight	X
INSM Insmed Morgan Stanley
$39

INSM Insmed, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.